Lower Drug Costs for Families Act
Lower Drug Costs for Families Act
Plain Language Summary
# Lower Drug Costs for Families Act (HR 2554) – Plain Language Summary **What the Bill Does** This bill would extend Medicare's drug rebate rules to private health insurance. Currently, drug manufacturers must pay rebates to the government when brand-name drugs without generic alternatives cost $100+ per year and increase faster than inflation. The bill would apply these same rebate requirements to drugs covered by private insurance plans. It would also change the baseline year for calculating rebates from 2021 back to 2016, potentially affecting how rebates are calculated. **Who It Affects** The bill primarily affects people with private health insurance, drug manufacturers, and insurance companies.
Drug manufacturers could face new requirements to issue rebates on commercial drugs, while private insurers and their members might see changes in drug pricing and coverage. This differs from current law, which only applies rebate rules to Medicare. **Current Status** The bill is currently in committee and has not yet been voted on by the full House. As of now, it remains in the early stages of the legislative process.
CRS Official Summary
Lower Drug Costs for Families Act This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance. Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).
Latest Action
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.